New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareCardiogen vs Vilon

Cardiogen vs Vilon

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Cardiogen
Immune SupportAnti-Aging & Longevity
Vilon
Summary
Cardiogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Arg) developed by Professor Vladimir Khavinson. It is a tissue-specific bioregulator for the heart and myocardium, designed to normalize cardiomyocyte function and support cardiac tissue regeneration. Research has demonstrated cardioprotective effects, improved cardiac rhythm, and benefits in recovery from ischemic injury.
Vilon is a synthetic dipeptide (Lys-Glu) derived from the thymus gland extract Thymalin. The shortest immune-regulatory peptide known, Vilon modulates T-cell and NK-cell function, extends lifespan in animal models, and shows epigenetic anti-aging activity. It is one of the Khavinson peptide bioregulators.
Half-Life
Short (minutes); gene-regulatory effects persist longer
Very short as a free dipeptide; effects mediated via gene regulation
Admin Route
SubQ, Oral
SubQ, Oral
Research
Typical Dose
10 mg per day
1–2 mg SC daily or 5–10 mg oral daily
Frequency
Daily for 10–30 days
Once daily
Key Benefits
  • Cardioprotective effects on myocardial tissue
  • Normalization of cardiomyocyte protein synthesis
  • May improve cardiac rhythm and conduction
  • Support for recovery from ischemic cardiac events
  • Anti-aging effects on heart tissue
  • Potential reduction in cardiac fibrosis
  • Often combined with Epithalon for comprehensive cardiovascular longevity support
  • Immune system modulation and restoration
  • Lifespan extension (30–40% in animal studies)
  • T-cell and NK-cell activation
  • Epigenetic anti-aging activity
  • Reduces oxidative stress markers
  • Antioxidant gene upregulation
  • May prevent age-related immune senescence
  • Anti-tumor immune surveillance
Side Effects
  • Generally well tolerated in available research
  • Mild injection site reactions
  • No significant adverse cardiovascular events reported at standard doses
  • Excellent safety profile, decades of Russian clinical use
  • Rare: mild injection site reaction
  • Very rare: mild allergic reaction
Stacks With